4521 — KAKEN PHARMACEUTICAL Share News
0.000.00%
Last trade - 00:00- ¥145bn
- ¥91bn
- ¥77bn
Table: Kaken Pharmaceutical -2025/26 group results
Table: Kaken Pharmaceutical -2025/26 parent forecast
Table: Kaken Pharmaceutical -2025/26 group forecast
Table: Kaken Pharmaceutical - 9-MTH group results
development Agreement for Multispecific Antibody NM81 in IBD
Table: Kaken Pharmaceutical - 6-MTH group results
Table: Kaken Pharmaceutical -2025/26 group forecast
Table: Kaken Pharmaceutical -Q1 group results
Table: Kaken Pharmaceutical -2024/25 group results
Table: Kaken Pharmaceutical -2024/25 group forecast
Alumis jumps on licensing deal for skin drug
Brief: Alumis And Kaken Pharmaceutical Announce Collaboration And Licensing Agreement For ESK-001 In Dermatology In Japan
To Buy Back And Cancel Up To 4.52% Outstanding Shares
Table: Kaken Pharmaceutical - 9-MTH group results
To Sell 2.29 Million Treasury Shares To Johnson & Johnson Innovation For 9.9 Billion Yen
Aadi Bioscience gains on licensing agreement for cancer drugs
To Acquire Aadi Subsidiary Inc For $100 Million
Table: Kaken Pharmaceutical - 6-MTH group results
Table: Kaken Pharmaceutical -2024/25 group forecast